Gosset Sera Medicines General Information
Sera Medicines operates as a biologics-focused accelerator that advances next-generation protein therapeutics targeting complex diseases. The company incubates programs internally until key value inflection points are reached, then spins out new companies—such as Tenet Medicines and Navigator Medicines—to drive these assets into the clinic. Notable recent results include the launch of Navigator Medicines with a $100M Series A financing for its lead bispecific antibody program targeting autoimmune disease. Sera’s approach enables rapid progression from discovery through clinical development by leveraging deep expertise across biology, chemistry, antibody engineering, manufacturing, and business operations.
Contact Information
Drug Pipeline
Key Partnerships
RA Capital Management (primary investor/partner)
Sera Medicines Funding
No funding data available